In the extensive comment by Zimmer et al 1 on our article 2 three points of criticism are expressed: (1) a simultaneous publication dealing with the same topic 3 has not been cited, (2) neg cells are NK-T cells, which to some extent mediate natural cytotoxicity towards tumor targets, is not new 5, 6 we have not discussed it explicitly in our paper. Nevertheless (and most importantly), our observation that neither CD56
In the extensive comment by Zimmer et al 1 on our article 2 three points of criticism are expressed: (1) a simultaneous publication dealing with the same topic 3 has not been cited, (2) 3 we have cited the earlier work by this group 4 on the assessment of NK-cell activity by CD107a surface expression in the introduction of our article.
Second, the analysis of CD3 pos CD56 pos NK-T cells (after staining with anti-CD3 FITC mAb, anti-CD56 PE and antiCD107a PE-Cy5) revealed that ca 2% of these cells degranulated in response to K562 cells. Since the finding that a part of the CD56 dim CD16
neg cells are NK-T cells, which to some extent mediate natural cytotoxicity towards tumor targets, is not new 5, 6 we have not discussed it explicitly in our paper. Nevertheless (and most importantly), our observation that neither CD56 pos /CD16 pos NK cells are able to kill K562 target cells, as indicated in chromium release cytotoxicity assays. 7, 8 We apologize that we have not further discussed this incongruity by ourselves and so far cannot provide a convincing explanation for these discrepant but clear results. However, there are many examples for scientific progress through results that are somehow discrepant to previous and well-established assumptions. We hope that our reply has helped to clarify methodological aspects and that our findings may have stimulated the discussion in this field. 
